LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP ... “there is little prospect of demonstrating a benefit in the primary ...

Resecurity, a U.S.-based cybersecurity firm, has partnered with Middle East Telecommunications Company (METCO) to enhance ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Some $935,000 would go toward replacing more than half of the approximately 1,300 laptop computers used by Macomb County ...

INDIGO is the largest clinical trial conducted in patients living with IgG4-RD--Topline INDIGO results expected by the end of 2025-WALTHAM, ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

He said IT benefits from the interns as much as the interns ... “The shift in security has moved from the endpoint and perimeter protection — trying to stop stuff in through our firewalls and things ...

AppOmni, the leader in SaaS security, announced today that CRN ®, a brand of The Channel Company has recognized AppOmni as a 2024 Stellar Security Startup. This prestigious list highlights fast-rising ...

Urgent action is needed to combat the cybersecurity trade-off which is putting patient’s health and wellbeing at risk. By Darren Williams ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Hello, everyone, and welcome to the N-able Third Quarter 2024 Earnings Call. My name is Chach, and I’ll be coordinating your call today.

The poster presentation suggested that adult patients with r/r B-ALL achieve comparable outcomes irrespective of the timing of stem cell transplant (SCT) pre or post obe-cel, suggesting no further ...

Along with the proven security achievements, this capacity to extend zero trust security to existing infrastructure could ...